Recommendation : "Patient prioritization regarding the disposal fo therapeutic means against COVID-19 (monoclonal antibodies)"
Athens, 18 December 2021
The NCBT discussed the issue of treatment prioritization for coronavirus, following a relevant request and accompanying note from the Ministry of Health.
The issue has occurred due to the availability of monoclonal antibody therapy in a limited number of doses, compared to the number of potential recipients among confirmed cases of the disease in the population.
It must be noted that the monoclonal antibody therapy is only suitable for the early stages of COVID-19, before the patient’s possible hospitalization. This expands the circle of potential recipients in large groups of the population, which makes prioritization a particularly complex problem.